iRhythm Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $IRTC in the last 7 days.
No SEC Form 4 filings for $IRTC in the last 30 days.
See all $IRTC insider activity →iRhythm Technologies disclosed a data breach affecting up to 8.2 million users, confirmed in an Oregon AG filing. The breach includes proprietary data and patient health information. The company received extortion demands but did not disclose if it paid. iRhythm is a cardiac monitoring firm with SEC filings.
iRhythm Holdings (IRTC) rose after Piper Sandler initiated coverage with an Overweight rating and $160 price target, citing an overdone year-to-date selloff. Analyst Adam Maeder made the argument.
iRhythm Technologies Inc. is notifying at least 370,000 patients that their health information was stolen in a cyber incident. The company reported the breach to the SEC in June and has submitted breach reports to several state attorneys general. The actual total size of the breach is unclear, with some reports estimating nearly 8.2 million people affected.
Recent IRTC coverage spans financial news, regulation and mergers & acquisitions.
Wider breach scope raises regulatory, litigation, and remediation risk, likely pressuring sentiment and increasing compliance costs.
Analyst upgrade with a high target suggests upside potential.
Breach disclosure raises near-term operational, regulatory, and litigation risk, even though the company says clinical systems and devices were unaffected.
iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.
Freedom Capital Markets kept a Buy rating and $190 price target on iRhythm Holdings, implying 74.2% upside from the Oct 5 close. The firm expects $1B+ revenue by 2027, 70%+ gross margin, and 15%+ EBITDA margin. The VitalConnect acquisition could add $65M in revenue within 12 months.
AlphAI scores every news story that mentions IRTC with an AI model for sentiment and relevance, and aggregates insider trades from iRhythm Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
iRhythm Technologies disclosed a data breach affecting up to 8.2 million users, confirmed in an Oregon AG filing. The breach includes proprietary data and patient health information. The company received extortion demands but did not disclose if it paid. iRhythm is a cardiac monitoring firm with SEC filings.
5 min readiRhythm Holdings (IRTC) rose after Piper Sandler initiated coverage with an Overweight rating and $160 price target, citing an overdone year-to-date selloff. Analyst Adam Maeder made the argument.
1 min readiRhythm Technologies Inc. is notifying at least 370,000 patients that their health information was stolen in a cyber incident. The company reported the breach to the SEC in June and has submitted breach reports to several state attorneys general. The actual total size of the breach is unclear, with some reports estimating nearly 8.2 million people affected.
6 min readiRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.
3 min readFreedom Capital Markets kept a Buy rating and $190 price target on iRhythm Holdings, implying 74.2% upside from the Oct 5 close. The firm expects $1B+ revenue by 2027, 70%+ gross margin, and 15%+ EBITDA margin. The VitalConnect acquisition could add $65M in revenue within 12 months.
1 min readWells Fargo lowered its price target on iRhythm Technologies (IRTC) to $150 from $168, citing updated models post-VitalPatch acquisition. IRTC trades at $109.09 with a $3.6B market cap. Analysts expect 62% upside. Q2 revenue was $224.2M, beating estimates. IRTC raised 2026 revenue guidance, targeting 15% adjusted EBITDA margin by 2027.
2 min readiRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.
3 min readiRhythm Holdings (IRTC) reported that a June cyberattack accessed patient data, including names, contact info, and insurance numbers. The company is notifying affected individuals.
1 min readiRhythm Holdings (IRTC) reported data exfiltration in third-party apps from June 3-8, 2026, affecting patient and insurance data. The company began notifying impacted individuals and stated no material financial impact is expected. This follows a previous breach disclosure in June 2026.
1 min readiRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer
1 min read
